FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma

Season 3 Episode 5  ·  May 21, 2020, 06:58 PM

Headliner
Share
Subscribe

We had the pleasure of speaking with Maria-Victoria Mateos, MD, PhD, to discuss the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

Share
Subscribe
Next
Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air